PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?

Dirk Arnold, MD, PhD Released: October 5, 2021

How might the use of PARP inhibitors evolve in the treatment of pancreatic cancer? Read this commentary from Dr Philip Philip.

Philip Agop Philip, MD, PhD, FRCP Released: January 31, 2022

Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: October 26, 2021

In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: November 3, 2021

Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.

Eileen M. O'Reilly, MD Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: February 21, 2022

In this downloadable PDF summary from a CCO podcast, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, compare the role and use of PARP inhibitors in the treatment of pancreatic cancer between the United States and Europe.

Eileen M. O'Reilly, MD Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

In this video roundtable, watch 3 experts give their perspectives on the optimal management of patients with pancreatic cancer using PARP inhibitors, as well as emerging strategies with PARP inhibitors that they find promising.

Dirk Arnold, MD, PhD Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: December 14, 2021 Expired: No longer available for credit

Assessing Mutations in Homologous Recombination Repair Genes: BRCA1/2 and Other Alterations

Personalizing First-line Chemotherapy and Maintenance PARP Inhibition Therapy Decisions

Clinical Pearls for Managing Patients on PARP Inhibitor Therapy

Future Directions for PARP Inhibition in Pancreatic Cancer

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.

Dirk Arnold, MD, PhD Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Released: December 14, 2021